NewAmsterdam Pharma (NASDAQ: NAMS) has appointed Adele Gulfo as an independent director to its board of directors. Ms. Gulfo is a pharmaceutical leader with over three decades of experience, known for her expertise in global strategy, operations leadership, and the commercialization of blockbuster medicines like Lipitor® and Crestor®.
NewAmsterdam Pharma is currently preparing for the potential launch of obicetrapib next year, and with the appointment of Ms. Gulfo, they aim to leverage her world-class commercial leadership and successful track record in launching blockbuster therapies on a global scale.
Ms. Gulfo served as the Chief Executive Officer for the biopharma commercial unit at Sumitomo Pharma America, Inc., overseeing the commercial and development portfolio across various therapeutic areas. She has also held significant roles at Sumitovant Biopharma, Roivant Sciences, and Pfizer, contributing to the successful launch preparations for major brands such as Orgovyx®, Gemtesa®, Rethymic®, and Myfembree®.
In addition to her executive roles, Ms. Gulfo currently serves on the board of directors of Tyra Biosciences and Enpro. She is also a member of the Innovation Growth Board at Mass General Brigham.
NewAmsterdam Pharma has recently had positive readouts from its three pivotal phase 3 clinical trials and is focused on improving patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated.
The company's mission is to fill a significant unmet need for a safe, well-tolerated, and convenient LDL-C lowering therapy. In multiple phase 3 trials, NewAmsterdam has investigated obicetrapib, an oral, low-dose, once-daily, highly selective cholesterol ester transfer protein ("CETP") inhibitor, as a preferred LDL-C lowering therapy to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Following these announcements, the company's shares moved 1.9%, and are now trading at a price of $16.34. If you want to know more, read the company's complete 8-K report here.
